Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna E Reece

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Current Opinion in Hematology|June 4, 2009
Recent trends in the management of newly diagnosed multiple myelomaDonna E Reece
Hematology. American Society of Hematology. Education Program|November 24, 2005
An update of the management of multiple myeloma: the changing landscapeDonna E Reece
International Journal of Hematologic Oncology|October 11, 2018
Management of multiple myeloma: the impact of ixazomib's approval in CanadaDonna E Reece
Hematology. American Society of Hematology. Education Program|December 14, 2011
Posttransplantation maintenance therapy and optimal frontline therapy in myelomaDonna E Reece
Current Opinion in Oncology|March 7, 2002
Hematopoietic stem cell transplantation in Hodgkin diseaseDonna E Reece
Blood|October 9, 2012
Carfilzomib in multiple myeloma: gold, silver, or bronze?Donna E Reece
Blood|April 15, 2017
Breaking bad…proteinsDonna E Reece
Blood Reviews|September 1, 2007
Management of multiple myeloma: the changing landscapeDonna E Reece
Blood|October 9, 2025
Mel200 or BuMel conditioning in myeloma: is there a winner?Donna E Reece
Leukemia & Lymphoma|May 8, 2015
The risk of secondary primary malignancies after therapy for multiple myelomaNuchanan Areethamsirikul, Donna E Reece
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Current Opinion in Hematology|June 4, 2009
Recent trends in the management of newly diagnosed multiple myelomaDonna E Reece
Hematology. American Society of Hematology. Education Program|November 24, 2005
An update of the management of multiple myeloma: the changing landscapeDonna E Reece
International Journal of Hematologic Oncology|October 11, 2018
Management of multiple myeloma: the impact of ixazomib's approval in CanadaDonna E Reece
Hematology. American Society of Hematology. Education Program|December 14, 2011
Posttransplantation maintenance therapy and optimal frontline therapy in myelomaDonna E Reece
Current Opinion in Oncology|March 7, 2002
Hematopoietic stem cell transplantation in Hodgkin diseaseDonna E Reece
Blood|October 9, 2012
Carfilzomib in multiple myeloma: gold, silver, or bronze?Donna E Reece
Blood|April 15, 2017
Breaking bad…proteinsDonna E Reece
Blood Reviews|September 1, 2007
Management of multiple myeloma: the changing landscapeDonna E Reece
Blood|October 9, 2025
Mel200 or BuMel conditioning in myeloma: is there a winner?Donna E Reece
Leukemia & Lymphoma|May 8, 2015
The risk of secondary primary malignancies after therapy for multiple myelomaNuchanan Areethamsirikul, Donna E Reece
Pageof 7